WINSTON-SALEM, N.C., June 25 /PRNewswire/ -- Targacept, Inc., a privately
held pharmaceutical research and development company, will present an update
of the company's progress at BIO 2001 International Investor and Partnering
Forum in San Diego.
(Photo: http://www.newscom.com/cgi-bin/prnh/20010517/CHTH002LOGO )
WHO: J. Donald deBethizy, Ph.D.
President and Chief Executive Officer
Targacept, Inc.
WHEN: June 27, 2001 at 2:00 p.m.
WHERE: BIO 2001 International Convention & Exhibition
San Diego Convention Center
Room A
San Diego, CA
A copy of Dr. deBethizy's presentation materials will be made available on
the company's web site http://www.targacept.com following the presentation.
Targacept is focused on the discovery and development of neuronal
nicotinic receptor-based therapies for neurodegenerative, neuropsychiatric and
gastrointestinal diseases. The company has products in research and
development for treating Alzheimer's disease, Parkinson's disease, ulcerative
colitis, depression, pain, attention deficit disorder and Tourette's syndrome,
among others.
Targacept was established in 1997 as a wholly owned subsidiary of R.J.
Reynolds Tobacco Company (NYSE: RJR). It was spun out in August 2000, in one
of the largest ($30.4 million) first-round venture capital financings in U.S.
biotech history and the largest in North Carolina biotech history. The
company has strategic alliances with Aventis Pharmaceuticals of Strasbourg,
France and Dr. Falk Pharma of Freiburg, Germany to develop and commercialize
Targacept compounds.
SOURCE Targacept, Inc.
 back to top
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20010517/CHTH002LOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Related links:
http://www.targacept.com
CONTACT:
Linda B. Gretton, Director of Communications
of Targacept, Inc., 336-741-2698
|
